You can buy or sell MGTA and other stocks, options, and ETFs commission-free!
Magenta Therapeutics, Inc. Common Stock, also called Magenta Therapeutics, is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA. The listed name for MGTA is Magenta Therapeutics, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Mar 9, Pre-Market